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1. Introduction 
1.1 Stemness 
The fertilized egg, also known as the zygote, is a cell of total potential and plasticity and 
gives rise to the embryo and extra-embryonic tissues, and ultimately the whole adult 
organism. This property has since been termed totipotency, although the transition from 
fertilized egg to differentiated cells of the adult tissues (somatic cells) is not direct, 
progressing instead through lineages of successively more differentiated and committed 
intermediates towards the final cell type. Thus, the zygote gives rise to the trophoblast 
cells and inner cell mass (ICM) of the blastocyst stage embryo, the ICM gives rise to the 
primordial cells committed to the ectodermal, mesodermal and endodermal lineages. To 
give an example lineage, the ectoderm cells give rise to the neural crest stem cells, then 
neural stem cells, oligodendrocyte precursors, and finally oligodendrocytes which 
myelinate and form the white matter of the central nervous system. Each step is more 
specialized and less plastic than the base or ‘stem’ of the branch before it. Unlike the 
totipotent zygote, these ‘stem cells’ retain the ability to self-renew in addition to their 
plasticity. In addition to giving rise to somatic tissues during embryogenesis, the 
biological role of stem cells in an adult organism is to regenerate tissues lost to injury, 
disease or age. 
1.2 History 
The first stem cells discovered were the originator cells of teratomas, a rare tumor that 
comprised of multiple tissue types and was associated with embryonal carcinoma (EC). 
These EC stem cells have the then-unusual ability to self-renew indefinitely, as well as give 
rise to tissues from each of the three germinal layers (Kleinsmith and Pierce, 1964), a 
property termed pluripotency. Since then, many more stem cell types of varying potency 
have been discovered, including two more pluripotent cell types: the embryonic stem cell 
(ESC) is a non-cancerous analogue of the EC stem cell which is derived instead from the 
ICM of blastocyst stage embryos (Evans and Kaufman, 1981), and most recently induced 
pluripotent stem cells (iPSCs) which are produced from somatic cells that have been 
reprogrammed to a pluripotent state (Takahashi and Yamanaka, 2006). Pluripotent cells 
have since been demonstrated to have enormous potential for regenerative medicine, 
disease research and genetic engineering.  
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2. Applications of pluripotent stem cells 
2.1 Animals from pluripotent cells 
ESCs are the prototypical pluripotent stem cell and thus the most thoroughly characterized. 
They can self-renew indefinitely and are effectively immortal in cell culture. Although they 
lack the self-organizing capabilities of the fertilized egg, they can form any tissue in the 
adult organism as demonstrated by two key studies: injecting ESCs into blastocysts gives 
rise to chimaeric animals with tissues contributed by the injected ESCs as well as the original 
ICM (Moustafa and Brinster, 1972); injection of ESCs into blastocysts that have been 
rendered tetraploid (four genome copies, and therefore genomically incapable of forming a 
complete organism) produces animals wholly derived from the injected ESCs (Eggan et al., 
2002). The latter technique is possible because tetraploid blastocysts retain the structural 
organization of a normal blastocyst, and although the tetraploid ICM will inevitably die out 
or senesce (and be replaced by the injected cells), the trophoblast component retains its 
function despite tetraploidy since trophoblasts eventually fuse and become polyploid 
anyway upon embryonic implantation into the maternal uterus. These properties are shared 
with all pluripotent cells, EC cells injected into blastocysts can also give rise to chimaeric 
animals (Mintz and Illmensee, 1975). Because of this potential, ESCs very quickly became a 
focus of applied research. 
2.2 ESCs in genetic engineering and animal disease modeling 
Modern reproduction techniques make it possible for a single ESC to give rise to a whole 
animal, greatly simplifying the process of genetically engineering animals. Previously, 
animals were bred extensively to isolate beneficial random mutations fertilized eggs were 
microinjected with DNA for random genomic integration (Gordon et al., 1980), or 
engineered animals were derived from nuclear-cloned somatic cells that had been 
engineered to the desired genotype; such a technique was used to generate cattle that lacked 
the prion protein and were thus made completely immune to bovine spongiform 
encephalopathy (BSE; mad cow disease, which transmits to humans as the variant 
Creutzfeldt-Jakob)(Richt et al., 2006). ESCs are easier to genetically engineer due to their 
infinite self-renewability, allowing a very small number of drug- or marker-selected cells to 
regenerate a whole culture or stable cell line. This technique has been used to generate a 
variety of mouse genetic models including sickle cell disease (Wu et al., 2006), thalassemia 
(Ciavatta et al., 1995), microcephaly (Pulvers et al., 2010), and T-cell lymphoma (Pechloff et 
al., 2010), as well as a p53-knockout rat for cancer research (Tong et al., 2010). 
2.3 In vitro disease modeling using pluripotent cells 
A major obstacle to disease research is the difficulty of acquiring diseased cells for study, 
usually because they are difficult to obtain from a living patient. For example, neurons are 
not easily obtained from a patient afflicted with Down syndrome, making detailed cell 
biology study of the neuronal basis for mental retardation impossible, and limiting our 
understanding of this disorder to more superficial behavioral neurological or postmortem 
pathological descriptions. However, a Down syndrome human ESC line as well as lines for 
other chromosomal trisomies have recently been derived (Biancotti et al., 2010), as has a 
human ESC line homozygous for Sickle Cell Disease (Pryzhkova et al., 2010). All were 
generated from embryos rejected by preimplantation genetic diagnosis (PGD) screens 
following in vitro fertilization (IVF). These lines allow cell culture study of diseased neurons, 
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or any other cell type, by differentiating diseased ESCs into any cell type of interest; 
however researchers are still limited by the small number of diseased human ESC lines 
available.  
Cloned embryos can be derived from adult cells using somatic cell nuclear transfer (SCNT), 
a technique made famous by the cloning of the sheep Megan, Morag and Dolly in the 1990s 
(Wilmut et al., 1997). It has been proposed that new diseased human ESC lines can be 
derived using this technique to make cloned embryos from diseased patients, and then 
harvesting them to create novel diseased ESC lines for disease study. At the time of this 
writing, SCNT for this application (Therapeutic Cloning) is currently legal in the United 
States and the European Union, but its legal status in these states as well as elsewhere across 
the world has been subject to numerous prior and continuing legal challenges. Although 
several large organizations continue to research this technology, it has been supplanted in 
recent years by alternate techniques for deriving patient-specific pluripotent stem cells. 
2.4 Therapeutic potential of pluripotent stem cells 
Pluripotent stem cells have been studied as, and shown great potential to be, a source of cell 
replacement therapies in a myriad of disease and injury models. Several human ESC lines 
have been differentiated into high-purity cardiomyocyte cultures that improve cardiac 
performance when transplanted into infracted rat hearts (Caspi et al., 2007). ESCs have also 
been differentiated into neural precursors and neurons including dopaminergic neurons 
which reverse the disease progression of Parkinsonian rats (Yang et al., 2008). In a model of 
spinal cord injury, ESC-derived oligodendrocytes transplanted into crushed rat spinal cords 
successfully restored locomotive function to the animals. Pancreatic beta cells, the insulin-
secreting cells whose absence causes type I diabetes mellitus, have also been derived from 
ESCs and cure the diabetic phenotype of the mouse streptozotocin-induced model of 
diabetes upon transplantation (Kim et al., 2003). These are but a choice selection of the vast 
amount of scientific literature detailing the regenerative potential of ESCs.  
At the time of this writing, two clinical trials are underway for ESC-based regenerative 
therapies in humans: an evaluation of human ESC-derived oligodendrocyte precursors to 
rescue neurologically complete spinal cord injury conducted by Geron Corporation, and 
ESC-derived retinal-pigmented epithelium for treatment of macular degeneration and 
Stargardt’s macular dystrophy, which are major causes of blindness, conducted by 
Advanced Cell Technology Incorporated. A third proposed clinical trial is currently in the 
approval process between the Food and Drug Administration and applicant California Stem 
Cell Incorporated for ESC-derived motor neurons as a cure for type I spinal muscular 
atrophy, the leading genetic cause of infant mortality. These trials represent the first step in 
the direct evaluation of the therapeutic potential of pluripotent stem cells in human patients. 
2.5 Pitfalls and obstacles to the use of ESCs 
Transplants of ESC-derived tissues and biological devices are just as subject to immune 
rejection as conventional organ transplants, even more so due to the limited selection of 
human ESC lines. Although the engineering of non-immunogenic ESCs has been the subject 
of many academic initiatives and company startups, ongoing clinical and preclinical 
research for ESC-therapies is focused, for the mean time, on immune-privileged regions of 
the body: specifically the brain, eye and spinal cord. A second scientific concern is the purity 
of ESC-derived transplants because of the hazard posed by contaminating undifferentiated 
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ESCs that, if transplanted, can proliferate and form teratomas. The elimination of these 
leftover ESCs has been approached by several strategies: purification of differentiated cells 
by labeling and cell sorting (Pruszak et al., 2007), the engineering of special “suicide gene”-
containing ESCs (Schuldiner et al., 2003), and the treatment of cells to be transplanted with 
chemotherapeutics (Bieberich et al., 2004). The concomitant destruction of stem cells by anti-
cancer therapies reflects the generalized similarity between stem cells and cancer cells 
[reviewed in (Reya et al., 2001)]. 
As many as seven human embryos are sacrificed for each new human ESC line derived 
(Thomson et al., 1998); while the ethics of this are philosophically subjective they have 
nonetheless given rise to numerous high-profile legal challenges to continued ESC research 
and funding. In addition, the patent on derivation of human ESC lines is held by the 
Wisconsin Alumni Research Foundation. Until its expiration in 2016, commercial users 
wishing to use Wisconsin ESC (“WiCell”) technologies might also be required to pay a royalty.  
3. Induced pluripotency 
3.1 Discovery 
The laboratory of Shinya Yamanaka demonstrated in 2006 that somatic cells can be 
reprogrammed back to a primordial phenotype functionally identical to ESCs, and termed 
these reprogrammed cells induced pluripotent stem cells (iPSCs)(Takahashi and Yamanaka, 
2006). These iPSCs have a morphology, growth and gene expression characteristics that are 
indistinguishable from ESCs. Like ESCs they also form teratomas consisting of tissues from 
all three germ layers when injected into immunodeficient animals (Takahashi and 
Yamanaka, 2006), and give rise to entire animals when injected into tetraploid blastocysts 
(Kang et al., 2009). iPSCs also have stable telomere lengths like ESCs (Marion et al., 2008) as 
well as an epigenetic state reflecting reversion back to pluripotency, although traces of the 
donor cell’s epigenetic imprint are retained in early-passage iPSCs (Kim et al., 2010).  
Pluripotency is typically induced by overexpressing in somatic cells the stem cell genes 
Oct3/4, Sox2, cMyc and Klf4 (Takahashi and Yamanaka, 2006) (collectively termed the 
Yamanaka factors) or by an alternate combination of Oct3/4, Sox2, Nanog and Lin28 (Yu et 
al., 2007) (the Thomson factors; this repertoire has not been extensively replicated in the 
literature). Retroviruses or lentiviruses are the standard vectors for inserting and over-
expressing these transgenes for a period of 2-3 weeks. During which the formation of early 
ESC-like colonies are observed [Figure 1]. These colonies stain positively for alkaline 
phosphatase, a marker which distinguishes undifferentiated cells from fibroblasts, and 
when clonally selected and propagated they express the ESC markers SSEA-1 and Oct3/4 
and assume a phenotype indistinguishable from ESCs (Takahashi and Yamanaka, 2006). 
3.2 Molecular mechanisms of induced pluripotency 
Induced pluripotency is a remarkably successful technique, although our understanding of the 
underlying mechanisms are limited. The Yamanaka combination of reprogramming factors 
wasn’t arrived at by a serendipitous leap of understanding, but instead careful and methodical 
experimentation. When Yamanaka sought to reprogram skin cells into ESCs, he began with a 
list of 24 candidate genes identified by extensive review of ESC literature. Overexpression in 
fibroblasts for two weeks gave rise to ESC-like colonies expressing the pluripotency marker 
Fbxo15. After a yearlong process of elimination, his lab was able to replicate this result with 
just 4 genes: Oct3/4, Sox2, cMyc and Klf4 (Takahashi and Yamanaka, 2006). 
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It has been known for some time that Oct3/4, Sox2 and Nanog comprise the core of the 
pluripotency transcriptional network, as the deficiency in either one causes ES cells to lose 
pluripotency (Avilion et al., 2003; Mitsui et al., 2003; Nichols et al., 1998). It is interesting to 
note, however, that too much Oct3/4 or Sox2 can also disrupt pluripotency. As little as a 
two-fold excess in either causes ESCs to differentiate (Kopp et al., 2008; Niwa et al., 2000).  
Oct3/4, Sox2 and Nanog all occupy each others’ promoters, and more than 90% of 
promoters bound to by Oct3/4 and Sox2 are also occupied by Nanog (Boyer et al., 2005). 
Although all three are required for pluripotency, Nanog overexpression is not required for 
induced pluripotency. Adding Nanog to the mix, however, increases reprogramming, as 
does combining the Yamanaka and Thomson reprogramming repertoires (Liao et al., 2008).  
 
 
Fig. 1. Generation of iPSCs. A: Although there are a number of ways to generate iPS Cells, 
the model reprogramming experiment uses lentiviral vectors to integrate the Yamanaka 
factor transgenes into skin fibroblasts and over-express them for a period of three weeks. 
After this period of time, stem cell-like colonies become apparent in the reprogrammed 
culture which, following selection and characterization, will give rise to stable iPS Cell 
lines. B: Fibroblasts before reprogramming have typical morphology and grow in 
confluent cell monolayers. C: iPS Cells, however, grow in dense, elevated and round 
colonies with the characteristic “glass edge.” They are microscopically indistinguishable 
from ESC cultures. 
The use of the RNA-binding protein Lin28 as one of the Thomson factors suggested a role 
for microRNAs during the reprogramming process, and since then a number of 
pluripotency-regulating microRNAs have been identified (Zhong et al., 2010). Of particular 
interest is the miR-302 family of microRNAs, which induce stem cell-like plasticity when 
overexpressed in skin cancer cells (Lin et al., 2008). 
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Reprogramming to pluripotency is accompanied by the demethylation of promoter regions 
of known pluripotency genes, and this is observed in both iPSCs (Park et al., 2008b) and 
cloned embryos generated by SCNT (Lan et al., 2010). In partially or incompletely 
reprogrammed cells generated by either method, this demethylation is incomplete (Bourchis 
et al., 2001; Takahashi and Yamanaka, 2006). Likewise, chromatin alterations are also 
observed in reprogrammed cells as well as cloned embryos, and both of these processes are 
enhanced by histone deacetylase inhibitors (Han et al., 2010). Histone demethylation, 
particularly at the promoters of pluripotency genes, is also observed but it is not understood 
how this occurs during induced pluripotency. 
3.3 The cancer generalization 
Despite the success and reproducibility of this reprogramming technique, the permanent 
integration of additional copies of stem cell genes with high expression promoters poses a 
significant oncogenic hazard; in the earlier studies one in five chimaeric mice derived from 
iPSCs died from tumors resulting from spontaneous reactivation of reprogramming genes 
(Okita et al., 2007). Although the Yamanaka and Thomson factors are highly expressed in 
ESCs, they are either oncogenes themselves or associated with a poor clinical outcome when 
detected in cancers. cMyc specifically is one of the most well-characterized oncogenes, but 
Oct3/4 expression in animals also results in death due to extreme proliferation of 
undifferentiated progenitors (Hochedlinger et al., 2005). [Oct3/4 actually has no known role 
outside of pluripotent biology and when conditionally deleted in adult animals results in no 
detectable phenotype or defect in healing (Lengner et al., 2007)]. Oct3/4 (Gidekel et al., 2003) 
and Sox2 (Gangemi et al., 2009) are associated with cancer cell proliferation and tumor 
progression, while Klf4 has been linked to an invasive progression and metastasis in 
epithelial cancers (Pandya et al., 2004). 
While the carcinogenic hazard introduced by genetic insertion of the Yamanaka factors led 
to a search for alternative reprogramming techniques, the generalization that ESCs and 
iPSCs biologically resemble cancer cells gave rise to a new line of thought: emulating 
oncogenesis to enhance reprogramming. Both SV40 Large T Antigen and TERT have been 
shown to enhance reprogramming when included in the Yamanaka factor repertoire (Park 
et al., 2008b), as has the knockout or knockdown of the tumor suppressor p53 
[simultaneously discovered by 5 separate groups and reviewed in (Krizhanovsky and Lowe, 
2009)]. The finding that adult stem cell populations, including hematopoietic (Eminli et al., 
2009), keratinocyte (Aasen et al., 2008) and neural (Kim et al., 2008) stem cells, reprogram 
more easily than the more differentiated cells further down their lineages is also consistent 
with the understanding that adult stem cells are most prone to becoming cancerous. 
Although these studies contribute greatly to our understanding of induced pluripotency 
and stem cell biology, incorporating them into current techniques to enhance 
reprogramming has, until quite recently, been impossible, as doing so would greatly 
enhance the oncogenic hazards. 
In recent years, a number of alternative techniques have emerged that induce pluripotency 
without genomic integration of the Yamanaka factors. Plasmid vectors have been used to 
induce pluripotency (Okita et al., 2008), however this technique has low reprogramming 
efficiency and half of the putative iPSCs generated contained some form of genomic 
integration. Adenoviruses also achieve reprogramming at a lowered efficiency; however a 
fraction of reprogrammed cells displayed karyotypic abnormalities (Stadtfeld et al., 2008). 
www.intechopen.com
 
iPS Cells: Born-Again Stem Cells for Biomedical Applications 
 
685 
Two other approaches favor transgene insertion followed by excision upon completion of 
reprogramming but also have their shortfalls: a retrotransposon vector which very rarely 
completely excises from the genome (Woltjen et al., 2009), and Cre-Lox recombination 
leaving behind residual sequences (Soldner et al., 2009). Most promising, however, are two 
DNA-free methods of reprogramming: direct delivery of recombinant transcription factors 
to the donor cells (Kim et al., 2009) and transfection with modified mRNAs encoding the 
Yamanaka factors (Warren et al., 2010). Although these last two methods achieve 
reprogramming with reduced efficiency, they circumvent the permanent oncogenic hazard 
presented by genomic integration of the Yamanaka factors (and any supplemental genes as 
well) and are most likely to be used for translational iPSC applications. 
3.4 Advantages of induced pluripotency 
Because they are derived from somatic cells and thus genetically autologous to the donor, 
iPSCs circumvent most of the obstacles, which have prevented clinical implementation of 
ESC technology. Moreover, being patient-specific they are not subject to immune rejection, 
and because induced pluripotency is an embryo-free method of deriving new pluripotent 
cell lines they are not subject to the funding restrictions or ethical controversies on ESC-
derivation. The field of iPSC research is unlikely to see the sort of legal challenges that ESC 
research has, having drawn endorsements from social conservatives including Republicans 
in America and the Catholic Church. 
iPSCs have several advantages in addition to overcoming ESC-specific obstacles. On a 
technique level, iPSCs are easier to derive than ESCs, and iPSC lines have already been 
derived from several species for which no ESC lines exist (Esteban et al., 2009; Li et al., 2009; 
Tomioka et al., 2010; Wu et al., 2009). This is because the optimal conditions for deriving 
ESCs vary across species [for example, human ESCs are maintained with basic fibroblast 
growth factor, while mouse ESCs are maintained with leukemia inhibitory factor], while 
induced pluripotency is conserved across mammals. Practically, this means induced 
pluripotency can facilitate easier genetic engineering of animals, as the most consistent and 
controlled techniques involve engineering of pluripotent stem cells. iPSC-based engineering 
of cattle and pigs is therefore becoming a new focus of the field [reviewed in (Telugu et al., 
2010)]. 
Induced pluripotency has also become the key technique for deriving diseased pluripotent 
cells. Whereas several ESC lines modeling karyotypic abnormalities (Biancotti et al., 2010) 
and sickle cell disease (Pryzhkova et al., 2010) exist, derivation of new diseased ESC lines is 
limited to PGD-rejected embryos from in vitro fertilization. However, in the three years since 
induced pluripotency was first described in humans, iPSC lines representative of a large 
number of genetic diseases have been derived including amyotrophic lateral sclerosis, 
adenosine deaminase severe combined immunodeficiency, Shwachman-Bodian-Diamond 
syndrome, Gaucher disease type III, muscular dystrophies, Parkinson’s disease, 
Huntington’s disease, juvenile-onset type-1 diabetes, Down’s syndrome, Lesch-Nyhan 
syndrome carrier, Fanconi anemia, spinal muscular atrophy, long-QT syndrome and 
familial dysautonomia and LEOPARD syndrome (Dimos et al., 2008; Ebert et al., 2009; Park 
et al., 2008a; Raya et al., 2009; Lee et al., 2009; Carvajal-Vergara et al., 2010; Moretti et al., 
2010). The utility of these lines is their ability to give rise to diseased tissue in vitro for study 
as well as drug testing [Figure 2], whereas previously, research on these diseases and many 
others has been impeded.  
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Fig. 2. Biomedical applications of iPSCs. Because iPSCs are patient-specific, neither they nor 
any cells derived from them are subject to transplant rejection. In this paradigm, easily 
obtained somatic cells such as skin fibroblasts or blood lymphocytes are reprogrammed to 
iPSCs, and therapeutic cells are derived from them to regenerate damaged or diseased 
tissue. In the case of the patient with a genetic disease, patient-specific iPSCs allow the 
derivation of genetically diseased tissues, which then could be subject to downstream 
research. 
4. Reprogramming techniques 
4.1 SCNT and induced pluripotency 
The first experiments to demonstrate that a terminally differentiated phenotype could be 
reprogrammed to pluripotency took place in the mid 1990s with the generation of cloned 
animals, the most famous of which were Dolly the sheep and her counterparts. Megan and 
Morag (Wilmut et al., 1997). In these experiments, donor cell nuclei were transplanted into 
enucleated oocytes, a technique termed somatic cell nuclear transfer (SCNT). Upon 
receiving a diploid genome, the re-nucleated oocytes assumed a zygote phenotype, which 
formed embryos and eventually whole animals. Although these experiments were critical in 
showing somatic cells can be epigenetically reprogrammed to pluripotency, animals cloned 
by SCNT were argued to begin life not with the long telomeres typical of early-stage 
embryonic cells, but instead with the aged and shortened telomeres of their nuclear donors- 
in the case of Dolly, an adult mammary epithelial cell. However, this claim remains 
controversial and has been refuted by a study that used cloned cattle (Lanza et al., 2000), 
and a recent demonstration that mice could be continuously cloned through 15 generations 
without any appreciable age-related issues or cloning efficiency (Thuan et al., 2010). 
Yamanaka’s demonstration, ten years later, that somatic cells could be directly 
reprogrammed into a pluripotent state by the over-expression of exogenous Oct3/4, Sox2, 
cMyc and Klf4, did not suffer from telomere problems because the resulting iPSCs express 
telomerase at high levels, quickly extending the reprogrammed cells’ telomeres to ESC-like 
lengths. However, introducing these transgenes using integrating retroviral vectors also 
brought about the risk of oncogenesis, and subsequent studies have attempted to 
circumvent this through one of three approaches: inserting the transgenes in a transient or 
www.intechopen.com
 
iPS Cells: Born-Again Stem Cells for Biomedical Applications 
 
687 
easily-excisable manner, reprogramming through the use of fewer transgenes, or 
reprogramming without the use of genome-integrating vectors.  
4.2 Excision of reprogramming transgenes 
Variations of the Yamanaka technique induce transient expression using non-integrating 
plasmids (Okita et al., 2008) or adenoviral vectors (Stadtfeld et al., 2008) and have produced 
isogenic pluripotent stem cells after many treatments, but with poor yields (in both cases, < 
0.0005%). Poor reprogramming efficiency makes necessary large donor sample sizes and 
high multiplicities of vector transfection. Additionally, half of iPSCs reprogrammed by 
plasmids had genomic integration. Although the incidence of this is reduced by the use of 
Adenoviral vectors, karyotypic abnormalities were observed in 23% of iPSC lines produced. 
Nonetheless, these experiments demonstrate reprogramming without genome integration. 
Retrotransposon elements (Woltjen et al., 2009) and cre-lox excision (Soldner et al., 2009) 
have also been used to insert and subsequently remove integrated transgenes, however 
complete removal of transgenes occurred at only 2% efficiency in the retrotransposon-
reprogrammed cells and 18% of excisions still left trace sequences in the genomic DNA. The 
efficiency of cre-lox excision was not demonstrated, but was consistently noted to leave 
proviral trace sequences. 
4.3 Use of fewer transgenes 
Reprogramming without using c-Myc has been demonstrated (Nakagawa et al., 2008) at 
1.6% the efficiency of the standard technique of when all four genes are used. c-Myc is the 
most hazardous of the reprogramming factors, and its omission in this experiment reduced 
tumor formation in mouse chimeras past the observation period. The histone deacytelase 
inhibitor valproate has been shown to enhance reprogramming efficiency >100-fold 
(Huangfu et al., 2008a) and can substitute for the Klf4 transgene in reprogramming 
(Huangfu et al., 2008b), at reduced efficiency. The histone methyltransferase inhibitor 
BIX01294 and L-channel Ca2+ agonist BayK8644, when used together, can replace the Sox2 
transgene (Shi et al., 2008) at reduced efficiency. No approach has yet replaced Oct3/4, 
which appears to be absolutely essential for reprogramming and is also the most reliable 
pluripotency marker. Reprogramming of different somatic cell types with fewer transgenes 
has yielded varying results. Neuronal stem cells (NSCs) have been reprogrammed to 
pluripotency using just Oct3/4 (Kim, 2009) and at improved efficiencies using Oct3/4 and 
Sox2 (Kim et al., 2008).  
4.4 Direct treatment with pluripotency factors 
Despite concerns with telomere length, SCNT remains the gold standard of induced 
pluripotency demonstrating that induced pluripotency can be accomplished through an 
entirely non-genetic approach (albeit with very low efficiency). This is echoed by recent 
experiments: somatic cells, when fused with pluripotent cells (either ESCs or iPSCs) always 
produce binucleate cells with both nuclei in a pluripotent state (Sumer et al., 2009). 
Furthermore, induced pluripotency has been demonstrated at extremely low (0.006%) 
efficiencies through the use of recombinant pluripotent factors (Kim et al., 2009) with 
multiple treatments over an 8-week period.  
Permeablization of somatic cells using bacterial pore-forming toxins, and then treating them 
with whole cell extracts from the desired cell phenotype has shown some promise in 
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epigenetic reprogramming, but so far no such experiments have generated induced 
pluripotent stem cells. In one such study, human 293T epithelial cells treated with T cell 
extracts, assume a phenotype similar to T-cells, and a neuronal-like phenotype when treated 
with neural precursor extracts (Hakelien et al., 2002).  Numerous attempts have been made to 
induce pluripotency by using extracts from ESCs, ECs, iPSCs and oocytes (Taranger et al., 
2005; Zhu et al., 2010), however none of these have succeeded in producing stable iPSC lines. 
5. Critical thinking on induced pluripotency 
Although iPSCs are highly similar to ESCs in biology and function, an increasing body of 
literature describes defects and subtle differences between the two pluripotent cell types. 
Effective characterization of these phenomena is critical and will likely give rise to new and 
more stringent criteria by which reprogrammed cells can be evaluated for suitability. 
One of the earliest characterizations of reprogrammed cells was the demonstration of DNA 
demethylation on the promoters of genes involved in pluripotency, such as Oct3/4 and 
Nanog (Okita et al., 2007; Takahashi and Yamanaka, 2006). Although these promoters 
exhibited near-total demethylation, indicating an activation of gene transcription, the 
demethylation was rarely as complete as the pattern observed in ESCs, and this was 
particularly true for early-passage (newly-created) iPSCs. Although these differences were 
small, genome-wide analysis of methylation patterns outside of these specific genes has 
revealed significant errors in epigenetic reprogramming (Lister et al., 2011). On a genomic 
scale, iPSC and ESC methylomes are similar, but most iPSC methylomes analyzed had 
megabase-sized loci of aberrant DNA methylation, which persist long after reprogramming 
and even after differentiation.  Some of these loci are shared among distinct iPSC lines, 
suggesting that certain regions of the methylomes are susceptible to aberrant and 
incomplete reprogramming. There have also been reports of differences in gene expression 
patterns between ESCs and iPSCs, although a recent study found that most of these 
differences are laboratory-specific and can be attributed to microenvironment differences in 
growth conditions from one laboratory to the next (Newman and Cooper, 2010). 
DNA sequence defects have also been described in iPSCs. Early-passage iPSCs display a 
range of polymorphism in copy number variant (CNV) regions compared to their parental 
fibroblasts (Hussein et al., 2011). As with DNA methylation, it was also found that CNVs 
occurred more commonly in “fragile regions” of the genome. As CNVs arise from damaged 
DNA improperly repaired by homologous recombination, this phenomenon suggests DNA 
damage and replicative stress in cells undergoing reprogramming. However, while early-
passage iPSCs contain significantly more CNVs, a vast majority of these mutations put the 
cells at a selective disadvantage. Mid- to late-passage iPSCs therefore lose CNVs and soon 
approach a genomic state highly similar to ESCs. Point mutations in specific genes have also 
been identified in iPSCs, however unlike CNVs these display a nonrandom pattern of 
enrichment, with a majority occurring in proto-oncogenes and tumor suppressors (Gore et 
al., 2011). Half of these mutations can be traced back to the parental fibroblasts, which 
harbor these mutations in low frequencies; however the other half most likely arise during 
reprogramming and, more importantly, the subsequent selection and propagation steps. 
Oncogenic mutations are generalized to give a selective advantage to pluripotent cells, and 
although an accumulation in oncogenic mutations has also been demonstrated in ESCs, this 
study still establishes the need for extensive genetic testing of iPSCs before they are to be 
used on a clinical scale. 
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6. Conclusions 
Although induced pluripotency as a reprogramming technique currently brings significant 
concerns about carcinogenicity as well as genomic and epigenomic integrity, a significant 
portion of the ESC research community has jumped ship in recent years in order to study 
iPSCs. This is because of the exciting promise these cells hold, as well as the mainstream 
belief that the obstacles that come with them will be overcome. With applications in a 
variety of fields including regenerative therapies, disease modeling, animal cloning and 
genetic engineering, induced pluripotency is actively transforming the stem cell community.  
Given how young the field is, induced pluripotency has a surprisingly well-developed body 
of basic research, which has already contributed enormously to our understanding on 
developmental biology and epigenetics, as well as given us insights on a large number of 
modeled genetic diseases. Taken together, the current body of literature on induced 
pluripotency describes why it is a very exciting time to be a part of this field. 
7. References 
Aasen, T., Raya, A., Barrero, M., Garreta, E., Consiglio, A., Gonzalez, F., Vassena, R., Bilic, J., 
Pekarik, V., Tiscornia, G., Edel, M., Boue, S. & Izpisua-Belmonte, J. (2008). Efficient 
and rapid generation of induced pluripotent stem cells from human keratinocytes. 
Nature Biotechnology, Vol.26, No.11, (October 2008), pp. 1276-1284, ISSN 1087-0156 
Avilion, A., Nicolis, S., Pevny, L., Perez, L., Vivian, N. & Lovell-Badge, R. (2003). 
Multipotent cell lineages in early mouse development depend on SOX2 function. 
Genes and Development, Vol.17, No.1, (January 2003), pp. 126-140, ISSN 1549-5477 
Biancotti, J., Narwani, K., Buehler, N., Mandefro, B., Golan-Lev, T., Yanuka, O., Clark, A., 
Hill, D., Benvenisty, N. & Lavon, N. (2010). Human embryonic stem cells as models 
for aneuploid chromosomal syndromes. Stem Cells, Vol.28, No.9, (September 2010), 
pp. 1530-1540, ISSN 1549-4918 
Bieberich, E., Silva, J., Wang, G., Krishnamurthy, K. & Condie, B. (2004). Selective apoptosis 
of pluripotent mouse and human stem cells by novel ceramide analogues prevents 
teratoma formation and enriches for neural precursors in ES cell-derived neural 
transplants. The Journal of Cell Biology, Vol.167, No.4, (November 2004), pp. 723-734, 
ISSN 1540-8140 
Bourchis, D., Le-Bourhis, D., Patin, D., Niveleau, A., Comizzoli, P., Renard, P. & Viegas-
Pequignot, E. (2001). Delayed and incomplete reprogramming of chromosome 
methylation patterns in bovine cloned embryos. Current Biology, Vol.11, No.19, 
(October 2001), pp. 1542-1546, ISSN 0960-9822 
Boyer, L., Lee, T., Cole, M., Johnstone, S., LEvine, S., Zucker, J., Guenther, M., Kumar, R., 
Murray, H., Jennifer, R., Gifford, D., Melton, D., Jaenisch, R. & Young, R. (2005). 
Core transcriptional regulatory circuitry in human embryonic stem cells. Cell, 
Vol.122, No.6, (September 2005), pp. 947-956, ISSN 0092-8674 
Carvajal-Vergara, X., Sevilla, A., D'Souza, S.L., Ang, Y.S., Schaniel, C., Lee, D.F., Yang, L., 
Kaplan, A.D., Adler, E.D., Rozov, R., Ge, Y., Cohen, N., Edelmann, L.J., Chang, B., 
Waghray, A., Su, J., Pardo, S., Lichtenbelt, K.D., Tartaglia, M., Gelb, B.D. & 
Lemischka, I.R. (2010). Nature, Vol.465, No.7299, (June 2010), pp. 808-812, ISSN 
0028-0836 
www.intechopen.com
 
Biomedical Science, Engineering and Technology 
 
690 
Caspi, O., Huber, I., Kehat, I., Habib, M., Arbel, J., Gepstein, A., Yankelson, L., Aronson, D., 
Beyar, R. & Gepstein, L. (2007). Transplantation of Human Embryonic Stem Cell-
Derived Cardiomyocytes Improves Myocardial Performance in Infarcted Rat 
Hearts. Journal of the American College of Cardiology, Vol.50, No.19, (October 2007), 
pp. 1884-1893, ISSN 1558-3597 
Ciavatta, D., Ryan, T., Farmer, S. & Townes, T. (1995). Mouse model of human beta zero 
thalassemia: targeted deletion of the mouse beta maj- and beta min-globin genes in 
embryonic stem cells. PNAS, Vol.92, No.20, (September 1995), pp. 9259-9263, ISSN 
0027-8424 
Dimos, J.T., Rodolfa, K.T., Niakan, K.K., Weisenthal, L.M., Mitsumoto, H., Chung, W., Croft, 
G.F., Saphier, G., Leibel, R., Goland, R., Wichterle, H., Henderson, C.E. & Eggan, K. 
(2008). Science, Vol.321, No.5893, (August 2008), pp. 1218-1221, ISSN 1095-9203 
Ebert, A.D., Yu, J., Rose, F.F. Jr., Mattis, V.B., Lorson, C.L., Thomson, J.A. & Svendsen, C.N. 
(2009). Induced pluripotent stem cells from a spinal muscular atrophy patient. 
Nature, Vol.457, No.7227, (January 2009), pp.277-280, ISSN 0028-0836 
Eggan, K., Rode, A., Jentsch, I., Samuel, C., Hennek, T., Tintrup, H., Zevnik, B., Erwin, K., 
Loring, J., Jackson-Grusby, L., Speicher, M., Kuehn, R. & Jaenisch, R. (2002). Male 
and female mice derived from the same embryonic stem cell clone by tetraploid 
embryo complementation. Nature Biotechnology, Vol.20, No.5, (May 2002), pp. 455-
459, ISSN 1087-0156 
Eminli, S., Foudi, A., Stadtfield, M., Maherali, N., Ahfeldt, T., Mostoslavsky, G., Hock, H. & 
Hochedlinger, K. (2009). Differentiation stage determines potential of 
hematopoietic cells for reprogramming into induced pluripotent stem cells. Nature 
Genetics, Vol.41, No.9, (September 2009), pp. 968-976, ISSN 1546-1718 
Esteban, M., Xu, J., Yang, J., Peng, M., Qin, D., Li, W., Jiang, Z., Chen, J., Deng, K., Zhong, 
M., Cai, J., Lai, L. & Pei, D. (2009). Generation of induced pluripotent stem cell lines 
from Tibetan Miniature Pig. Journal of Biological Chemistry, Vol.284, No.26, (June 
2009), pp. 17634-17640, ISSN 0021-9258 
Evans, M. & Kaufman, M. (1981). Establishment in culture of pluripotential cells from 
mouse embryos. Nature, Vol.292, No.5819, (July 1981), pp. 154-156, ISSN 0028-0836 
Gangemi, R., Griffero, F., Marubbi, S., Perera, M., Capra, M., Malatesta, P., Ravetti, G., Zona, 
G., Daga, A. & Corte, G. (2009). SOX2 silencing in glioblastoma tumor-initiating 
cells causes stop of proliferation and loss of tumorigenicity. Stem Cells, Vol.27, No.1, 
(January 2009), pp. 40-48, ISSN 1549-4918 
Gidekel, S., Pizov, G., Bergman, Y. & Pikarsky, E. (2003). Oct-3/4 is a dose-dependent 
oncogenic fate determinant. Cancer Cell, Vol.4, No.5, (November 2003), pp. 361-370, 
ISSN 1535-6108 
Gordon, J., Scangos, G., Plotkin, D., Barbarosa, J. & Ruddle, F. (1980). Genetic transformation 
of mouse embryos by microinjection of purified DNA. PNAS, Vol.77, No.12, 
(December 1980), pp. 7380-7384, ISSN 0027-8424 
Gore, A., Li, Z., Fung, H., Young, J., Agarwal, S., Antosiewicz-Bourget, J., Canto, I., 
Giorgetti, A., Israel, M., Kiskinis, E., Lee, J., Loh, Y., Manos, P., Montserrat, N., 
Panopoulos, A., Ruiz, S., Wilbert, M., Yu, J., Kirkness, E., Belmonte, J., Rossi, D., 
Thomson, J. & Eggan, K., Daley, G., Goldstein, L., Zhang, K. (2011). Somatic coding 
mutations in human induced pluripotent stem cells. Nature, Vol.471, No.7336, 
(March 2011), pp. 63-72, ISSN 1476-4687 
www.intechopen.com
 
iPS Cells: Born-Again Stem Cells for Biomedical Applications 
 
691 
Hakelien, A., Landsverk, H., Robl, J., Skalhegg, B. & Collas, P. (2002). Reprogramming 
fibroblasts to express T-cell functions using cell extracts. Nature Biotechnology, 
Vol.20, No.5, (May 2002), pp. 460-466, ISSN 1087-0156 
Han, J., Sachdev, P. & Sidhu, K. (2010). A combined epigenetic and non-genetic approach for 
reprogramming human somatic cells. PLoS ONE, Vol.5, No.8, (August 2010), pp. 
12297, ISSN 1932-6203 
Hochedlinger, K., Yamada, Y., Beard, C. & Jaenisch, R. (2005). Ectopic expression of Oct-4 
blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell, 
Vol.121, No.3, (May 2005), pp. 465-477, ISSN 0092-8674 
Huangfu, D., Maehr, R., Guo, W., Eijkelenboom, A., Snitow, M., Chen, A. & Melton, D. 
(2008a). Induction of Pluripotent stem cells by defined factors is greatly improved 
by small-molecule compounds. Nature Biotehcnology, Vol.26, No.7, (July 2008), pp. 
795-797, ISSN 1546-1696 
Huangfu, D., Osafune, K., Maehr, R., Guo, W., Eijkelenboom, A., Chen, S., Muhlestein, W. & 
Melton, D. (2008b). Induction of pluripotent stem cells from primary human 
fibroblasts with only Oct4 and Sox2. Nature Biotehcnology, Vol.26, No.11, 
(November 2008), pp. 1269-1275, ISSN 1546-1696 
Hussein, S., Batada, N., Vuoristo, S., Ching, R., Autio, R., Narva, E., Ng, S., Sourour, M., 
Hamalainen, R., Olsson, C., Lundin, K., Mikkola, M., Trokovic, R., Peitz, M., 
Brustle, O., Bazett-Jones, D., Alitalo, K., Lahesmaa, R., Nagy, A. & Otonkoski, T. 
(2011). Copy number variation and selection during reprogramming to 
pluripotency. Nature, Vol.471, No.7336, (March 2011), pp., ISSN 1476-4687 
Kang, L., Wang, J., Zhang, Y., Kou, Z. & Gao, S. (2009). iPS Cells Can Support Full-Term 
Development of Tetraploid Blastocyst-Complemented Embryos. Cell Stem Cell, 
Vol.5, No.2, (August 2009), pp. 135-138, ISSN 1875-9777 
Kim, D., Gu, Y., Ishii, M., Fujimiya, M., Qi, M., Nakamura, N., Yoshikawa, T., Sumi, S. & 
Inoue, K. (2003). In vivo functioning and transplantable mature pancreatic islet-like 
cell clusters differentiated from embryonic stem cell. Pancreas, Vol.27, No.2, 
(August 2003), pp. 34-41, ISSN 1536-4828 
Kim, D., Kim, C.H., Moon, J.I., Chung, Y.G., Chang, M.Y., Han, B.S., Ko, S., Yang, E., Cha, 
K.Y., Lanza, R. & Kim, K.S. (2009). Generation of human induced pluripotent stem 
cells by direct delivery of reprogramming proteins. Cell Stem Cell, Vol.4, No.6, (June 
2009), pp. 472-476, ISSN 1875-9777 
Kim, J. (2009). Oct4-induced pluripotency in adult neural stem cells. Cell, Vol.136, No.3, 
(February 2009), pp. 411-419, ISSN 1097-4172 
Kim, J., Zaehres, H., Wu, G., Gentile, L., Ko, K., Sebastiano, V., Arauzo-Bravo, M., Ruau, D., 
Han, D., Zenke, M. & Scholer, H. (2008). Pluripotent stem cells induced from adult 
neural stem cells by reprogramming with two factors. Nature, Vol.454, No.7204, 
(July 2008), pp. 646-650, ISSN 1476-4687 
Kim, K., Doi, A., Wen, B., Ng, K., Zhao, R., Cahan, P., Kim, J., Aryee, M., Ji, H., Ehrlich, L., 
Uabuuchi, A., Takeuchi, A., Cunniff, K., Hongguang, H., McKinney-Freeman, S., 
Naveiras, O., Yoon, T., Irizarry, R., Jung, N., Seita, J., Hanna, J., Murakami, P., 
Jaenisch, R., Weissleder, R., Orkin, S., Weissman, I., Feinberg, A. & Daley, G. (2010). 
Epigenetic memory in induced pluripotent stem cells. Nature, Vol.467, No.7313, 
(September 2010), pp. 285-290, ISSN 1476-4687 
www.intechopen.com
 
Biomedical Science, Engineering and Technology 
 
692 
Kleinsmith, L. & Pierce, G.J. (1964). Multipotentiality of Single Embryonal Carcinoma Cells. 
Cancer Res., Vol.24, No.1, (October 1964), pp. 1544-1551, ISSN 0008-5472 
Kopp, J., Ormsbee, B., Desler, M. & Rizzino, A. (2008). Small increases in the level of Sox2 
trigger the differentiation of mouse embryonic stem cells. Stem Cells, Vol.26, No.4, 
(April 2008), pp. 903-911, ISSN 1549-4918 
Krizhanovsky, V. & Lowe, S. (2009). Stem cells: The promises and perils of p53. Nature, 
Vol.460, No.7259, (August 2009), pp. 1085-1086, ISN 1476-4687 
Lan, J., Hua, S., Zhang, H., Song, Y., Liu, J. & Zhang, Y. (2010). Methylation patterns in 5' 
terminal regions of pluripotency-related genes in bovine in vitro fertilized and 
cloned embryos. Journal of Genetics and Genomics, Vol.37, No.5, (May 2010), pp. 297-
304, ISSN 1673-8527 
Lanza, R.P., Cibelli, J.B., Blackwell, C., Cristofalo, V.J., Francis, M.K., Baerlocher, G.M., Mak, 
J., Schertzer, M., Chavez, E.A., Sawyer, N., Lansdrop, P.M. & West, M.D. (2000). 
Extension of cell life-span and telomere length in animals cloned from senescent 
somatic cells. Science, Vol.288, No.5466, (April 2000), pp.665-669, ISSN 1095-9203. 
Lee, G., Papapetrou, E.P., Kim, H., Chambers, S.M., Tomishima, M.J., Fasano, C.A., Ganat, 
Y.M., Menon, J., Shimizu, F., Viale, A., Tabar, V., Sadelain, M. & Studer, L. (2009). 
Modelling parthenogenesis and treatment of familial dysautonomia using patient-
specific iPSCs. Nature, Vol.461, No.7262, (September 2009), pp. 402-406, ISSN 0028-
0836  
Lengner, C., Camargo, F., Hochedlinger, K., Welstead, G., Zaidi, S., Gokhale, S., Scholer, H., 
Tomilin, A. & Jaenisch, R. (2007). Oct4 Expression Is Not Required for Mouse 
Somatic Stem Cell Self-Renewal. Cell Stem Cell, Vol.1, No.4, (October 2007), pp. 403-
415, ISSN 1875-9777 
Li, W., Wei, W., Zhu, S., Zhu, J., Shi, Y., Lin, T., Hao, E., Hayek, A., Deng, H. & Ding, S. 
(2009). Generation of rat and human induced pluripotent stem cells by combining 
genetic reprogramming and chemical inhibitors. Cell Stem Cell, Vol.4, No.1, 
(January 2009), pp. 16-19, ISSN 1875-9777 
Liao, J., Wu, Z., Wang, Y., Cheng, L., Cui, C., Gao, Y., Chen, T., Rao, L., Chen, S., Jia, N., Dai, 
H., Xin, S., Kang, J., Pei, G. & Xiao, L. (2008). Enhanced efficiency of generating 
induced pluripotent stem (iPS) cells from human somatic cells by a combination of 
six transcription factors. Cell Research., Vol.18, No.5, (May 2008), pp. 600-603, ISSN 
1748-7838 
Lin, S., Chang, D., Chang-Lin, S., Lin, C., Wu, D., Chen, D. & Ying, S. (2008). Mir-302 
reprograms human skin cancer cells into a pluripotent ES-cell-like state. RNA, 
Vol.14, No.10, (October 2008), pp. 2115-2124, ISSN 1469-9001 
Lister, R., Pelizzola, M., Kida, Y., Hawkins, R., Nery, J., Hon, G., Antosiewcz-Bourget, J., 
O'Malley, R., Castanon, R., Klugman, S., Downes, M., Yu, R., Stewart, R., Ren, B., 
Thomson, J., Evans, R. & Ecker, J. (2011). Hotspots of aberrant epigenomic 
reprogramming in human induced pluripotent stem cells. Nature, Vol.471, No.7336, 
(March 2011), pp. 68-76, ISSN 1476-4687 
Marion, R., Strati, K., Li, H., Tejera, A., Schoeftner, S., Ortega, S., Serrano, M. & Blasco, M. 
(2008). Telomeres Acquire Embryonic Stem Cell Characteristics in Induced 
Pluripotent Stem Cells. Cell Stem Cell, Vol.6, No.4, (February 2009), pp. 141-154, 
ISSN 1875-9777 
www.intechopen.com
 
iPS Cells: Born-Again Stem Cells for Biomedical Applications 
 
693 
Mintz, B. & Illmensee, K. (1975). Normal genetically mosaic mice produced from malignant 
teratocarcinoma cells. PNAS, Vol.72, No.9, (September 1975), pp. 3585-3589, ISSN 
0027-8424 
Mitsui, K., Tokuzawa, Y., Itoh, H., Segawa, K., Murakami, M., Takahashi, K., Maruyama, M., 
Maeda, M. & Yamanaka, S. (2003). The Homeoprotein Nanog Is Required for 
Maintenance of Pluripotency in Mouse Epiblast and ES Cells. Cell, Vol.113, No.5, 
(May 2003), pp. 631-642, ISSN 0092-8674 
Moretti, A., Bellin, M., Welling, A., Jung, C.B., Lam, J.T., Bott-Flügel, L., Dorn, T., Goedel, A., 
Höhnke, C., Hofmann, F., Seyfarth, M., Sinnecker, D., Schömig, A. & Laugwitz, K.L. 
(2010). New England Journal of Medicine. Vol.363, No.15, (October 2010), pp. 1397-
1409, ISSN 0028-4793 
Moustafa, L. & Brinster, R. (1972). Induced chimaerism by transplanting embryonic stem 
cells into mouse blastocysts. Journal of Experimental Zoology, Vol.181, No.2, (August 
1972), pp. 193-201, ISSN 0022-104X 
Nakagawa, M., Koyanagi, M., Tanabe, K., Takahashi, K., Ichisaka, T., Aoi, T., Okita, K., 
Mochiduki, Y., Takizawa, N. & Yamanaka, S. (2008). Generation of induced 
pluripotent stem cells without Myc from mouse and human fibroblasts. Nature 
Biotechnology, Vol.26, No.1, (January 2008), pp. 101-106, ISSN 1546-1696 
Newman, A. & Cooper, J. (2010). Lab-specific gene expression signatures in pluripotent stem 
cells. Cell Stem Cell, Vol.7, No.2, (August 2010), pp. 258-262, ISSN 1875-9777 
Nichols, J., Zevnik, B., Anastassiadis, K., Niwa, H., Klewe-Nebenius, D., Chambers, I., 
Scholer, H. & Smith, A. (1998). Formation of Pluripotent Stem Cells in the 
Mammalian Embryo Depends on the POU Transcription Factor Oct4. Cell, Vol.95, 
No.3, (October 1998), pp. 379-391, ISSN 0092-8674 
Niwa, H., Miyazaki, J. & Smith, A. (2000). Quantitative expression of Oct-3/4 defines 
differentiation, dedifferentiation or self-renewal of ES cells. Nature Genetics, Vol.24, 
No.4, (April 2000), pp. 372-376, ISSN 1061-4036 
Okita, K., Ichisaka, T. & Yamanaka, S. (2007). Generation of germline-competent induced 
pluripotent stem cells. Nature, Vol.448, No.7151, (July 2007), pp. 313-317, ISSN 1476-
4687 
Okita, K., Nakagawa, M., Hyenjong, H., Ichisaka, T. & Yamanaka, S. (2008). Generation of 
mouse induced pluripotent stem cells without viral vectors. Science, Vol.322, 
No.5903, (November 2008), pp. 949-953, ISSN 1095-9203 
Pandya, A., Talley, L., Frost, A., Fitzgerald, T., Trivedi, V., Chakravarthy, M., Chieng, D., 
Grizzle, W., Engler, J., Krontiras, H., Bland, K., LoBuglio, A., Lobo-Ruppert, S. & 
Ruppert, J. (2004). Nuclear Localization of KLF4 is Associated with an Aggressive 
Phenotype in Early-Stage Breast Cancer. Clinical Cancer Research, Vol.10, No.8, 
(April 2004), pp. 2709-2719, ISSN 1078-0432 
Park, I., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., Lensch, M., Cowan, 
C., Hochedlinger, K. & Daley, G. (2008a). Disease-Specific Induced Pluripotent 
Stem Cells. Cell, Vol.134, No.5, (September 2008), pp. 877-886, ISSN 1097-4172 
Park, I., Zhao, R., West, J., Yabuuchi, A., Huo, H., Ince, T., Lerou, P., Lensch, M. & Daley, G. 
(2008b). Reprogramming of human somatic cells to pluripotency with defined 
factors. Nature, Vol.451, No.7175, (January 2008), pp. 141-146, ISSN 1476-4687 
Pechloff, K., Holch, J., Ferch, U., Schweneker, M., Brunner, K., Kremer, M. & Sparwasser, T. 
(2010). The fusion kinase ITK-SYK mimics a T cell receptor signal and drives 
www.intechopen.com
 
Biomedical Science, Engineering and Technology 
 
694 
oncogenesis in conditional mouse models of peripheral T cell lymphoma. Journal of 
Experimental Medicine, Vol.207, No.5, (May 2010), pp. 1031-1044, ISSN 1540-9538 
Pruszak, J., Sonntag, K., Aung, M., Sanchez-Pernaute, R. & Isacson, O. (2007). Markers and 
methods for cell sorting of human embryonic stem cell-derived neural cell 
populations. Stem Cells, Vol.25, No.9, (September 2007), pp. 2257-2268, ISSN 1549-
4918 
Pryzhkova, M., Peters, A. & Zambidis, A. (2010). Erythropoietic differentiation of a human 
embryonic stem cell line harbouring the sickle cell anaemia mutation. Reproductive 
BioMedicine Online, Vol.21, No.2, (August 2010), pp. 196-205, ISSN 1472-6491 
Pulvers, J., Bryk, J., Fish, J., Brauninger, M., Arai, Y., Schreier, D., Naumann, R., Helppi, J., 
Habermann, B., Vogt, J., Nitsch, R., Toth, A., Enard, W., Paabo, S. & Huttner, W. 
(2010). Mutations in mouse Aspm (abnormal spindle-like microcephaly associated) 
cause not only microcephaly but also major defects in the germline. PNAS, Vol.107, 
No.38, (September 2010), pp. 16595-16600, ISSN 1091-6490 
Raya, A., Rodríguez-Pizà, I., Guenechea, G., Vassena, R., Navarro, S., Barrero, M.J., 
Consiglio, A., Castellà, M., Río, P., Sleep, E., González, F., Tiscornia, G., Garreta, E., 
Aasen, T., Veiga, A., Verma, I.M., Surrallés, J., Bueren, J. & Izpisúa Belmonte, J.C. 
(2009). Nature, Vol.460, No.7251, (July 2009), pp.53-59, ISSN 0028-0836 
Reya, T., Morrison, S., Clarke, M. & Weissman, I. (2001). Stem cells, cancer, and cancer stem 
cells. Nature, Vol.141, No.6859, (November 2001), pp. 105-111, ISSN 0028-0836 
Richt, J., Kasinathon, P., Hamir, A., Castilla, J., Sathyyaseelan, T., Vargas, F., Sathiyaseelan, 
J., Wu, H., Matsushita, H., Koster, J., Kato, S., Ishida, I., Soto, A., Robl, J. & Kuroiwa, 
Y. (2006). Production of cattle lacking prion protein. Nature Biotechnology, Vol.25, 
No.1, (January 2007), pp. 132-138, ISSN 1087-0156 
Schuldiner, M., Itskovitz-Eldor, J. & Benvenisty, N. (2003). Selective ablation of human 
embryonic stem cells expressing a "suicide" gene. Stem Cells, Vol.21, No.3, (May 
2003), pp. 257-265, ISSN 1066-5099 
Shi, Y., Desponts, C., Do, J., Hahm, H., Scholer, H. & Ding, S. (2008). Induction of 
Pluripotent Stem Cells from Mouse Embryonic Fibroblasts by Oct4 and Klf4 with 
Small-Molecule Compounds. Cell Stem Cell, Vol.3, No.5, (November 2008), pp. 568-
574, ISSN 1875-9777 
Soldner, F., Hockemeyer, D., Beard, C., Gao, Q., Bell, G., Cook, E., Hargus, G., Blak, A., 
Cooper, O., Mitalipova, M., Isacson, O. & Jaenisch, R. (2009). Parkinson's disease 
patient-derived pluripotent stem cells free of viral reprogramming factors. Cell, 
Vol.136, No.5, (March 2009), pp. 964-977, ISSN 1097-4172 
Stadtfeld, M., Nagaya, M., Utikal, J., Weir, G. & Hochedlinger, K. (2008). Induced 
pluripotent stem cells generated without viral integration. Science, Vol.322, 
No.5903, (November 2008), pp. 945-949, ISSN 1095-9203 
Sumer, H., Jones, K., Liu, J., Heffernan, C., Tat, P., Upton, K. & Verma, P. (2009). 
Reprogramming of somatic cells after fusion with iPS and ntES cells. Stem Cells & 
Development, Vol.19, No.2, (February 2010), pp. 239-246, ISSN 1557-8534 
Takahashi, K. & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse 
embryonic and adult fibroblast cultures by defined factors. Cell, Vol.126, No.4, 
(August 2006), pp. 663-676, ISSN 0092-8674 
Taranger, C., Noer, A., Sorensen, A., Hakeliel, A., Boquest, A. & Collas, P. (2005). Induction 
of dedifferentiation, genomewide transcriptional programming, and epigenetic 
www.intechopen.com
 
iPS Cells: Born-Again Stem Cells for Biomedical Applications 
 
695 
reprogramming by extract of carcinoma and embryonic stem cells. Molecular Biology 
of the Cell, Vol.16, No.12, (December 2005), pp. 5719-5735, ISSN 1059-1524 
Telugu, B., Ezashi, T. & Roberts, R. (2010). The Promise of stem cell research in pigs and 
other ungulate species. Stem Cell Reviews, Vol.6, No.1, (March 2010), pp. 31-41, ISSN 
1558-6804 
Thomson, J., Itskovitz-Eldor, J., Shapiro, S., Waknitz, M., Swiergiel, K., Marshall, V. & Jones, 
J. (1998). Embryonic stem cell lines derived from human blastocysts. Science, 
Vol.282, No.5391, (November 1998), pp. 1145-1147, ISSN 0036-8075 
Thuan, N. V., Kishigami, S. & Wakayama, T. (2010). How to improve the success rate of 
mouse cloning technology. Journal of Reproduction and Development, Vol.56, No.1, 
(January 2010), pp 20-30, ISSN 0916-8818.  
Tomioka, I., Maeda, T., Shimada, H., Kawai, K., Okada, Y., Igarashi, H., Oiwa, R., Iwasaki, 
T., Aoki, M., Kimura, T., Shiozawa, S., Shinohara, H., Suemizu, H., Sasaki, E. & 
Okano, H. (2010). Generating induced pluripotent stem cells from common 
marmoset (Callithrix jacchus) fetal liver cells using defined factors, including Lin28. 
Genes to Cells, Vol.15, No.9, (September 2010), pp. 959-969, ISSN 1365-2443 
Tong, C., Li, P., Wu, N., Yan, Y. & Ying, Q. (2010). Production of p53 gene knockout rats by 
homologous recombination in embryonic stem cells. Nature, Vol.467, No.7312, 
(September 2010), pp. 211-213, ISSN 1476-4687 
Warren, L., Manos, P., Ahfeldt, T., Loh, Y., Li, H., Lau, F., Ebina, W., Mandal, P., Smith, Z., 
Meissner, A., Daley, G., Brack, A., Collins, J., Cowan, C., Schlaeger, T. & Rossi, D. 
(2010). Highly efficient reprogramming to pluripotency and directed differentiation 
of human cells with synthetic modified mRNA. Cell Stem Cell, Vol.7, No.5, 
(November 2010), pp. 618-630, ISSN 1875-9777 
Wilmut, I., Schnieke, A., McWhir, J., Kind, A. & Campbell, K. (1997). Viable offspring 
derived from fetal and adult mammalian cells. Nature, Vol.385, No.6619, (February 
1997), pp. 810-813, ISSN 0028-0836 
Woltjen, K., Michael, I., Mohseni, P., Desai, R., Mileikovsky, M., Cowling, R.H.R., Wang, W., 
Liu, P., Gertsenstein, M., Kaji, K., Sung, H. & Nagy, A. (2009). PiggyBac 
transposition reprograms fibroblasts to induced pluripotent stem cells. Nature, 
Vol.458, No.7239, (April 2009), pp. 766-770, ISSN 1476-4687 
Wu, L., Sun, C., Ryan, T., Pawlik, K., Ren, J. & Townes, T. (2006). Correction of sickle cell 
disease by homologous recombination in embryonic stem cells. Blood, Vol.108, 
No.4, (August 2006), pp. 1183-1188, ISSN 0006-4971 
Wu, Z., Chen, J., Ren, J., Bao, L., Liao, J., Cui, C., Rao, L., Li, H., Gu, Y., Dai, H., Zhu, H., 
Teng, X., Cheng, L. & Xiao, L. (2009). Generation of pig induced pluripotent stem 
cells with a drug-inducible system. Journal of Molecular and Cellular Biology, Vol.1, 
No.1, (October 2009), pp. 46-54, ISSN 1759-4685 
Yang, D., Zhang, Z., Oldenburg, M., Ayala, M. & Zhang, S. (2008). Human Embryonic Stem 
Cell-Derived Dopaminergic Neurons Reverse Functional Deficit in Parkinsonian 
Rats. Stem Cells, Vol.26, No.1, (January 2008), pp. 55-63, ISSN 1549-4918 
Yu, J., Vodyanik, M., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J., Tian, S., Nie, J., 
Jonsdottir, G., Ruotti, V., Stewart, R., Slukvin, I. & Thomson, J. (2007). Induced 
pluripotent stem cell lines derived from human somatic cells. Science, Vol.318, 
No.5858, (December 2007), pp. 1917-1920, ISSN 1095-9203 
www.intechopen.com
 
Biomedical Science, Engineering and Technology 
 
696 
Zhong, X., Li, N., Liang, S., Huang, Q., Coukos, G. & Zhang, L. (2010). Identification of 
mircoRNAs regulating reprogramming factor Lin28 in embryonic stem cells and 
cancer cells. Journal of Biological Chemistry, Vol.285, No.53, (December 2010), pp. 
41961-41971, ISSN 1083-351X 
Zhu, X., Pan, X., Wang, W., Chen, Q., Pang, R., Cai, X., Hoffman, A. & Hu, J. (2010). 
Transient in vitro epigenetic reprogramming of skin fibroblasts into multipotent 
cells. Biomaterials, Vol.31, No.10, (April 2010), pp. 2779-2787, ISSN 1878-5905 
www.intechopen.com
Biomedical Science, Engineering and Technology
Edited by Prof. Dhanjoo N. Ghista
ISBN 978-953-307-471-9
Hard cover, 902 pages
Publisher InTech
Published online 20, January, 2012
Published in print edition January, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This innovative book integrates the disciplines of biomedical science, biomedical engineering, biotechnology,
physiological engineering, and hospital management technology. Herein, Biomedical science covers topics on
disease pathways, models and treatment mechanisms, and the roles of red palm oil and phytomedicinal plants
in reducing HIV and diabetes complications by enhancing antioxidant activity. Biomedical engineering coves
topics of biomaterials (biodegradable polymers and magnetic nanomaterials), coronary stents, contact lenses,
modelling of flows through tubes of varying cross-section, heart rate variability analysis of diabetic neuropathy,
and EEG analysis in brain function assessment. Biotechnology covers the topics of hydrophobic interaction
chromatography, protein scaffolds engineering, liposomes for construction of vaccines, induced pluripotent
stem cells to fix genetic diseases by regenerative approaches, polymeric drug conjugates for improving the
efficacy of anticancer drugs, and genetic modification of animals for agricultural use. Physiological engineering
deals with mathematical modelling of physiological (cardiac, lung ventilation, glucose regulation) systems and
formulation of indices for medical assessment (such as cardiac contractility, lung disease status, and diabetes
risk). Finally, Hospital management science and technology involves the application of both biomedical
engineering and industrial engineering for cost-effective operation of a hospital.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Ambrose Jon Williams and Vimal Selvaraj (2012). iPS Cells: Born-Again Stem Cells for Biomedical
Applications, Biomedical Science, Engineering and Technology, Prof. Dhanjoo N. Ghista (Ed.), ISBN: 978-953-
307-471-9, InTech, Available from: http://www.intechopen.com/books/biomedical-science-engineering-and-
technology/ips-cells-born-again-stem-cells-for-biomedical-applications
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
